Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2016
A novel UK approach to cancer access: yes, no, or maybe?
10 August 2016 - What are the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients? ...
Posted by Michael Wonder on 11 Aug 2016
1 September 2016 changes to PBS efficient funding of chemotherapy
11 August 2016 - From 1 September 2016, approved suppliers will need to provide additional information when claiming eligible efficient funding ...
Posted by Michael Wonder on 11 Aug 2016
CADTH provides an update on its therapeutic review of new drugs for type 2 diabetes mellitus
10 August 2016 - CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment ...
Posted by Michael Wonder on 10 Aug 2016
Cancer patients may lose vital drug in crackdown on funding: watchdog reviews 31 treatments that are not usually available on the NHS
10 August 2016 - The drug brentuximab vedotin may no longer be provided on the NHS. ...
Posted by Michael Wonder on 10 Aug 2016
PBAC Drug Utilisation Sub Committee outcome statement
10 August 2016 - The outcome statement from the PBAC Drug Utilisation Sub Committee June 2016 meeting is now available. ...
Posted by Michael Wonder on 10 Aug 2016
Proposal to award sole supply of venlafaxine hydrochloride
10 August 2016 - PHARMAC is seeking feedback on a proposal to award sole supply status in the community for venlafaxine hydrochloride ...
Posted by Michael Wonder on 09 Aug 2016
Adaptive pathways: EMA still leaves open questions unanswered
9 August 2016 - Current EMA report on the pilot project again documents perplexity regarding the use of “real world data”. ...
Posted by Michael Wonder on 09 Aug 2016
NICE issues draft guidance on the use of talimogene laherparepvec
9 August 2016 - Talimogene laherparepvec (Imlygic) is the first cellular therapy to be appraised by NICE. ...
Posted by Michael Wonder on 09 Aug 2016
Proposal to award sole supply of leflunomide
9 August 2016 - PHARMAC is seeking feedback on a proposal to award Sole Supply Status in the community for leflunomide to ...
Posted by Michael Wonder on 08 Aug 2016
CADTH issues final pERC outcome for Yondelis (trabectedin)
5 August 2016 - CADTH has published pERC's final recommendation on the use of trabectedin for patients with metastatic liposarcoma ...
Posted by Michael Wonder on 08 Aug 2016
SMC - August 2016 decisions
8 August 2016 - Treatments for blood cancer, skin cancer and high cholesterol among six new medicines accepted for routine use ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to enoxaparin sodium and plerixafor
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis New Zealand Limited (Sanofi) for ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to idarucizumab and dabigatran
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Boehringer Ingelheim NZ Limited for the ...
Posted by Michael Wonder on 06 Aug 2016
Brivaracetam in epilepsy: additional clinical benefits not seen as before
4 August 2016 - The new indirect comparison is methodologically better but there is still no evidence of an additional ...
Posted by Michael Wonder on 06 Aug 2016
CADTH calls for patient input on a submission from Cipher Pharmaceuticals for Actikerall (5-fluorouracil with salicylic acid)
5 August 2016 - CADTH is calling for patient input on a pending submission from Cipher Pharmaceuticals for Actikerall. ...